A Phase 2a, Randomized, Double-blind, Parallel Group, Placebo-controlled, Multi-center Study To Assess The Efficacy And Safety Profile Of Pf-06651600 In Subjects With Moderate To Severe Active Rheumatoid Arthritis With An Inadequate Response To Methotrexate
Phase of Trial: Phase II
Latest Information Update: 25 Jan 2018
At a glance
- Drugs PF 6651600 (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Pfizer
- 16 Jan 2018 Status changed from recruiting to completed.
- 18 Dec 2017 Planned End Date changed from 12 Dec 2017 to 1 Dec 2017.
- 28 Nov 2017 Planned number of patients changed from 120 to 60.